Brain repair: cell therapy in stroke

• Published in: Stem cells and cloning Vol. 7; no. default; pp. 31 - 44
• Main Authors: Kalladka, Dheeraj, Muir, Keith W
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2014; Taylor & Francis Ltd; Dove Medical Press
• Subjects: 20th century; Analysis; Bone marrow; Care and treatment; Cellular therapy; Clinical trials; Edema; Gene expression; Hospitals; Inflammation; Internet; Ischemia; Magnetic resonance imaging; Medical prognosis; Medicine; National libraries; Neurogenesis; Parkinson's disease; Review; Stem cells; Stroke; Stroke (Disease); Thromboembolism; Websites; United States > US; China; cerebrovascular disease; stroke; cell therapy; neurological disease
• ISSN: 1178-6957; 1178-6957
• DOI: 10.2147/SCCAA.S38003

Stroke affects one in every six people worldwide, and is the leading cause of adult disability. Some spontaneous recovery is usual but of limited extent, and the mechanisms of late recovery are not completely understood. Endogenous neurogenesis in humans is thought to contribute to repair, but its extent is unknown. Exogenous cell therapy is promising as a means of augmenting brain repair, with evidence in animal stroke models of cell migration, survival, and differentiation, enhanced endogenous angiogenesis and neurogenesis, immunomodulation, and the secretion of trophic factors by stem cells from a variety of sources, but the potential mechanisms of action are incompletely understood. In the animal models of stroke, both mesenchymal stem cells (MSCs) and neural stem cells (NSCs) improve functional recovery, and MSCs reduce the infarct volume when administered acutely, but the heterogeneity in the choice of assessment scales, publication bias, and the possible confounding effects of immunosuppressants make the comparison of effects across cell types difficult. The use of adult-derived cells avoids the ethical issues around embryonic cells but may have more restricted differentiation potential. The use of autologous cells avoids rejection risk, but the sources are restricted, and culture expansion may be necessary, delaying treatment. Allogeneic cells offer controlled cell numbers and immediate availability, which may have advantages for acute treatment. Early clinical trials of both NSCs and MSCs are ongoing, and clinical safety data are emerging from limited numbers of selected patients. Ongoing research to identify prognostic imaging markers may help to improve patient selection, and the novel imaging techniques may identify biomarkers of recovery and the mechanism of action for cell therapies.